Alkem Laboratories Dividend Record Date Tomorrow on February 20: Dividend to be Paid by March 06

Alkem Laboratories Ltd has decided to pay an interim dividend of ₹43 by March 02, 2026, for which the company set the February 20, 2026, as the record date to mark the eligibility criteria.

Alkem Laboratories said in an exchange filing, “The Board of Directors declared an Interim Dividend of Rs. 43/- (Rupees forty-three only) per equity share on the face value of Rs. 2/- per share for financial year 2025-2026 pursuant to Regulation 43 read with Regulation 30 of SEBI LODR Regulations. The date of payment of Interim Dividend shall be on and from 6 March 2026. 

Further, as informed vide our letter dated 23rd January 2026, submitted to the Stock Exchanges pursuant to Regulation 42 of SEBI LODR Regulations, the record date for the purpose of payment of Interim Dividend for the financial year 2025-2026 would be Friday, 201 h February 2026.” 

Can You Buy Alkem Laboratories Shares Today for Dividend Eligibility?

Alkem Laboratories has announced February 20 as the record date for its interim dividend. This means that February 19 is the last day to purchase Alkem Laboratories shares to be eligible for the dividend. Shares bought on or after the record date will not qualify for the interim dividend due to the T+1 settlement rule.

Also Read: IRCTC Dividend Record Date Tomorrow (Feb 20, 2026) – ₹3.50 Interim Payout Announced

Alkem Laboratories Management Take on Q3FY26 Earnings

Commenting on this development, Sandeep Singh, Managing Director, Alkem Laboratories, said, “This acquisition holds strategic importance as we work towards establishing a global footprint in medical devices. Occlutech is the third-largest player globally in the minimally invasive cardiac implants segment. With its significant presence in high-barrier markets, bestin-class R&D and manufacturing, and robust quality systems, Occlutech provides a strong lever for Alkem MedTech to expand into cardiovascular along with orthopaedics. Medtech is a natural extension for Alkem. In the company years, along with Enzene Biosciences, our Biotech arm, we expect Alkem MedTech to become a meaningful growth pillar for the company.”

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.